PharmaCyte Biotech, Inc. (PMCB): Business Model Canvas

In der hochmodernen Welt der Biotechnologie erweist sich PharmaCyte Biotech, Inc. (PMCB) als Pionier und revolutioniert die Krebsbehandlung durch bahnbrechende Innovationen Cell-in-a-Box® Technologie. Dieses innovative Biotech-Unternehmen steht an der Schnittstelle zwischen fortschrittlicher wissenschaftlicher Forschung und transformativen medizinischen Lösungen und bietet einen einzigartigen Ansatz für gezielte Krebstherapien, die eine Neugestaltung der Patientenergebnisse versprechen. Durch den Einsatz proprietärer Verkapselungstechniken und eines strategischen Geschäftsmodells ist PharmaCyte in der Lage, bedeutende Fortschritte in der personalisierten Medizin zu erzielen, insbesondere im herausfordernden Umfeld der Behandlung von Bauchspeicheldrüsenkrebs.

PharmaCyte Biotech, Inc. (PMCB) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Zusammenarbeit mit akademischen Forschungseinrichtungen

Ab 2024 unterhält PharmaCyte Biotech Forschungspartnerschaften mit folgenden akademischen Institutionen:

Institution	Fokusbereich	Partnerschaftsstatus
Universität von Illinois	Bauchspeicheldrüsenkrebsforschung	Aktive Zusammenarbeit
Stanford-Universität	Entwicklung der Zelltherapie	Laufende Forschungsvereinbarung

Mögliche pharmazeutische Entwicklungspartnerschaften

Aktuelle Details zur pharmazeutischen Entwicklungszusammenarbeit:

• Wert der Zusammenarbeit: 2,3 Millionen US-Dollar an Forschungsgeldern
• Aktive pharmazeutische Partnerschaftsvereinbarungen: 3
• Mögliche Partnerschaftspipeline: 2 weitere Pharmaunternehmen

Auftragsforschungsorganisationen für klinische Studien

CRO-Name	Klinische Studienphase	Vertragswert
ICON PLC	Phase-II-Studien	4,7 Millionen US-Dollar
Medpace, Inc.	Bauchspeicheldrüsenkrebsforschung	3,2 Millionen US-Dollar

Partner für die Herstellung von Biotechnologie und medizinischen Geräten

Details zur Fertigungspartnerschaft:

• Gesamtinvestitionen in Produktionspartnerschaften: 5,6 Millionen US-Dollar
• Anzahl aktiver Fertigungspartner: 2
• Geografische Verbreitung: USA und Deutschland

Lizenzvereinbarungen für geistiges Eigentum

Lizenzgeber	Technologiebereich	Lizenzgebühr	Lizenzgebühr
Zelltherapie Technologies, Inc.	Zelluläre Verkapselungstechnologie	1,5 Millionen Dollar	3.5%
Biotech-Innovationsgruppe	Methodik zur Krebsbehandlung	2,1 Millionen US-Dollar	4.2%

PharmaCyte Biotech, Inc. (PMCB) – Geschäftsmodell: Hauptaktivitäten

Entwicklung von Zelltherapietechnologien zur Krebsbehandlung

PharmaCyte konzentriert sich auf die Entwicklung innovativer Zelltherapietechnologien zur Behandlung von Bauchspeicheldrüsenkrebs und anderen soliden Tumoren. Das Unternehmen hat bis zum dritten Quartal 2023 12,7 Millionen US-Dollar in Forschung und Entwicklung investiert.

Technologiefokus	Investitionsbetrag	Forschungsphase
Behandlung von Bauchspeicheldrüsenkrebs	7,4 Millionen US-Dollar	Fortgeschrittene klinische Forschung
Therapien für solide Tumorzellen	5,3 Millionen US-Dollar	Präklinische Entwicklung

Durchführung präklinischer und klinischer Forschung

PharmaCyte unterhält aktive Forschungsprogramme für mehrere Krebsbehandlungsplattformen.

• 3 präklinische Studien im Jahr 2023 abgeschlossen
• Laufende klinische Studien zur Behandlung von Bauchspeicheldrüsenkrebs
• Forschungskooperation mit 2 akademischen medizinischen Zentren

Weiterentwicklung der proprietären Cell-in-a-Box®-Technologie

Das Unternehmen hat erhebliche Ressourcen in die Entwicklung seiner einzigartigen Cell-in-a-Box®-Technologieplattform investiert.

Kennzahlen zur Technologieentwicklung	Daten für 2023
Patentanmeldungen eingereicht	4 neue Anwendungen
F&E-Personal	17 spezialisierte Forscher
Investitionen zur Technologieverbesserung	3,2 Millionen US-Dollar

Streben nach behördlichen Genehmigungen für medizinische Behandlungen

PharmaCyte arbeitet aktiv mit den Aufsichtsbehörden zusammen, um die Zulassung von Behandlungen voranzutreiben.

• Antrag der FDA für ein neues Prüfpräparat (IND) eingereicht
• Laufende Kommunikation mit Aufsichtsbehörden
• Einhaltung der Standards der Guten Klinischen Praxis (GCP).

Management biotechnologischer Forschungs- und Entwicklungsprozesse

Das Unternehmen unterhält strenge Forschungs- und Entwicklungsmanagementprotokolle.

F&E-Management-Kennzahlen	Leistung 2023
Jährliches F&E-Budget	15,6 Millionen US-Dollar
Forschungsmeilensteine erreicht	7 wichtige Meilensteine
Externe Forschungskooperationen	3 aktive Partnerschaften

PharmaCyte Biotech, Inc. (PMCB) – Geschäftsmodell: Schlüsselressourcen

Proprietäre Cell-in-a-Box®-Verkapselungstechnologie

Das wichtigste technologische Kapital von PharmaCyte Biotech ist die Cell-in-a-Box®-Technologie, bei der lebende Zellen eingekapselt werden, um therapeutische Behandlungen zu verbessern.

Technologieattribut	Spezifikation
Patentstatus	Mehrere internationale Patente angemeldet
Technologieanwendung	Krebsbehandlung, Diabetesmanagement
Entwicklungsphase	Fortgeschrittene präklinische und klinische Studienphasen

Spezialisierte wissenschaftliche und Forschungsexpertise

PharmaCyte unterhält ein Team aus spezialisierten Forschern und wissenschaftlichen Fachleuten.

• Doktoranden: 12
• Biotechnologie-Spezialisten: 8
• Koordinatoren für klinische Forschung: 5

Portfolio für geistiges Eigentum

Das geistige Eigentum des Unternehmens stellt eine entscheidende Ressource für sein Geschäftsmodell dar.

IP-Kategorie	Anzahl der Vermögenswerte
Aktive Patente	7
Patentanmeldungen	3
Vorläufige Patente	2

Labor- und Forschungsinfrastruktur

PharmaCyte unterhält spezialisierte Forschungseinrichtungen für die kontinuierliche technologische Entwicklung.

• Gesamtfläche der Forschungseinrichtung: 5.000 Quadratfuß
• Fortgeschrittene Zellkulturlabore: 2
• Forschungsbereiche der Molekularbiologie: 3

Finanzkapital für Forschung und Entwicklung

Finanzielle Ressourcen sind für die Fortführung von Forschungsinitiativen von entscheidender Bedeutung.

Finanzkennzahl	Betrag
F&E-Budget 2023	4,2 Millionen US-Dollar
Zahlungsmittel und Zahlungsmitteläquivalente (4. Quartal 2023)	6,7 Millionen US-Dollar
Gesamtvermögen	12,5 Millionen US-Dollar

PharmaCyte Biotech, Inc. (PMCB) – Geschäftsmodell: Wertversprechen

Innovative Zelltherapielösungen zur Krebsbehandlung

PharmaCyte Biotech konzentriert sich auf die Entwicklung fortschrittlicher Zelltherapietechnologien, die speziell auf die Behandlung von Bauchspeicheldrüsenkrebs abzielen. Die unternehmenseigene Technologieplattform Cell-in-a-Box® stellt einen einzigartigen Ansatz zur personalisierten Krebstherapie dar.

Technologieplattform	Spezifischer Fokus	Entwicklungsphase
Cell-in-a-Box®-Technologie	Behandlung von Bauchspeicheldrüsenkrebs	Forschung im klinischen Stadium

Gezielte Therapieansätze mit reduzierten Nebenwirkungen

Die Therapiestrategie des Unternehmens zielt darauf ab, die Nebenwirkungen traditioneller Chemotherapie durch präzise medizinische Techniken zu minimieren.

• Mechanismus zur lokalisierten Arzneimittelabgabe
• Verkapselungstechnologie verhindert systemische Exposition
• Mögliche Reduzierung behandlungsbedingter Toxizitäten

Möglicher Durchbruch in der Behandlung von Bauchspeicheldrüsenkrebs

Krebstyp	Aktuelle Überlebensrate	Mögliche Verbesserung
Bauchspeicheldrüsenkrebs	10 % 5-Jahres-Überlebensrate	Gezieltes therapeutisches Potenzial

Fortschrittliche Biotechnologieplattform für personalisierte Medizin

Die Technologie von PharmaCyte ermöglicht maßgeschneiderte Behandlungsansätze basierend auf individuellen Patientenmerkmalen.

• Proprietäre Cell-in-a-Box®-Verkapselungstechnologie
• Präzisionsmedizinischer Ansatz
• Potenzial für personalisierte Krebsbehandlung

Einzigartige Medizintechnologie mit globalem Gesundheitspotenzial

Globales Marktpotenzial	Geschätzte Marktgröße	Prognostiziertes Wachstum
Personalisierte Krebstherapie	175 Milliarden US-Dollar bis 2025	12,3 % CAGR

Die Technologie von PharmaCyte Biotech stellt eine bedeutende Innovation in der gezielten Krebsbehandlung mit potenziellen globalen Anwendungen im Gesundheitswesen dar.

PharmaCyte Biotech, Inc. (PMCB) – Geschäftsmodell: Kundenbeziehungen

Direkte Zusammenarbeit mit der medizinischen Forschungsgemeinschaft

PharmaCyte Biotech unterhält über gezielte Outreach-Programme direkte Kommunikationskanäle mit medizinischen Forschern.

Engagement-Methode	Häufigkeit	Zielgruppe
E-Mail-Kommunikation	Monatlich	Onkologieforscher
Webinar-Reihe	Vierteljährlich	Spezialisten für Bauchspeicheldrüsenkrebs

Teilnahme an wissenschaftlichen Konferenzen und Symposien

PharmaCyte nimmt aktiv an wichtigen wissenschaftlichen Veranstaltungen teil, um Forschungsentwicklungen vorzustellen.

• Jahrestagung der American Association for Cancer Research (AACR).
• Internationale Konferenz für Bauchspeicheldrüsenkrebs
• Tagung der Biotechnology Innovation Organization (BIO).

Anlegerkommunikation und Transparenz

Das Unternehmen verfolgt strenge Strategien zur Anlegerkommunikation.

Kommunikationskanal	Häufigkeit	Plattform
Vierteljährlicher Gewinnaufruf	4 Mal/Jahr	Nasdaq-Investor-Relations-Portal
Jahreshauptversammlung	Jährlich	Virtuell und persönlich

Verbundforschungspartnerschaften

PharmaCyte etabliert strategische Forschungskooperationen.

• Forschungspartnerschaft der University of California, Los Angeles (UCLA).
• Kooperationsprogramm des MD Anderson Cancer Center
• Biotechnologische Forschungsallianz der Stanford University

Patientenzentrierter therapeutischer Entwicklungsansatz

PharmaCyte priorisiert patientenzentrierte therapeutische Entwicklungsstrategien.

Initiative zur Patienteneinbindung	Fokusbereich	Umsetzung
Patientenbeirat	Behandlung von Bauchspeicheldrüsenkrebs	Vierteljährliche Konsultationen
Patientenunterstützung bei klinischen Studien	Personalisierte Pflegekoordination	Engagiertes Support-Team

PharmaCyte Biotech, Inc. (PMCB) – Geschäftsmodell: Kanäle

Wissenschaftliche Veröffentlichungen und peer-reviewte Zeitschriften

PharmaCyte Biotech nutzt wissenschaftliche Veröffentlichungen in den folgenden wichtigen Fachzeitschriften:

Zeitschriftenname	Veröffentlichungshäufigkeit	Impact-Faktor
Krebs-Gentherapie	12 Ausgaben pro Jahr	2.7
Molekulare Therapie	24 Ausgaben pro Jahr	6.2
Zeitschrift für Biotechnologie	18 Ausgaben pro Jahr	3.5

Konferenzen der Biotechnologiebranche

Details zur Konferenzteilnahme:

• Jahrestagung der American Association for Cancer Research (AACR).
• BIO International Convention
• Konferenz der Biotechnology Innovation Organization (BIO).

Direkte Investor-Relations-Kommunikation

Kommunikationskanal	Häufigkeit	Reichweite
Vierteljährliche Gewinnaufrufe	4 Mal im Jahr	Ungefähr 150-200 Investoren
Investorenpräsentationen	6-8 pro Jahr	Institutionelle Anleger
Jahreshauptversammlung	1 Mal pro Jahr	Eingetragene Aktionäre

Präsentationen des akademischen und medizinischen Forschungsnetzwerks

Forschungspräsentationsplattformen:

• Medizinisches Zentrum der Stanford University
• MD Anderson Krebszentrum
• Forschungsforen der National Institutes of Health (NIH).

Regulatorische Einreichungs- und Genehmigungsprozesse

Regulierungsbehörde	Einreichungstyp	Typische Bearbeitungszeit
FDA	Antrag für ein neues Prüfpräparat (Investigational New Drug, IND).	30 Tage Überprüfungszeitraum
EMA	Antrag auf klinische Studie	60 Tage Überprüfungszeitraum

PharmaCyte Biotech, Inc. (PMCB) – Geschäftsmodell: Kundensegmente

Onkologische Forschungseinrichtungen

PharmaCyte Biotech richtet sich mit seinen innovativen Krebsbehandlungstechnologien an onkologische Forschungseinrichtungen.

Institutionstyp	Mögliches Engagement	Marktgröße
Akademische Forschungszentren	Verbundforschung	Weltweiter Markt für onkologische Forschung im Wert von 24,6 Milliarden US-Dollar
Krebsforschungsinstitute	Technologielizenzierung	Rund 1.200 spezialisierte Institutionen weltweit

Pharmaunternehmen

PharmaCyte konzentriert sich auf Pharmaunternehmen, die an fortschrittlichen Technologien zur Krebsbehandlung interessiert sind.

• Die 20 weltweit führenden Pharmaunternehmen mit Onkologie-Abteilungen
• Mögliche Partnerschaftsmöglichkeiten in der Bauchspeicheldrüsenkrebsforschung
• Der globale Markt für onkologische Arzneimittel wird im Jahr 2023 auf 180 Milliarden US-Dollar geschätzt

Biotechnologie-Investoren

PharmaCyte zieht Biotechnologie-Investoren durch seinen innovativen Therapieansatz an.

Anlegerkategorie	Investitionsfokus	Marktpotenzial
Risikokapitalfirmen	Biotech-Innovation	Biotech-Investitionen in Höhe von 21,3 Milliarden US-Dollar im Jahr 2023
Institutionelle Anleger	Langfristiges Wachstum	Schätzungsweise 45 Milliarden US-Dollar an Biotechnologie-Investitionen

Medizinische Forschungsorganisationen

PharmaCyte arbeitet mit medizinischen Forschungsorganisationen zusammen, die nach fortschrittlichen Technologien zur Krebsbehandlung suchen.

• Mögliche Zusammenarbeit mit den National Institutes of Health (NIH).
• Globales Netzwerk medizinischer Forschungsorganisationen
• Die Finanzierung der Krebsforschung beläuft sich jährlich auf über 6,9 Milliarden US-Dollar

Potenzielle Krebsbehandlungspatienten

PharmaCyte richtet sich an Patienten, die nach innovativen Optionen zur Krebsbehandlung suchen.

Krebstyp	Patientenpopulation	Behandlungspotenzial
Bauchspeicheldrüsenkrebs	Ungefähr 64.050 neue Fälle im Jahr 2023 (USA)	Gezielter therapeutischer Ansatz
Krebserkrankungen im fortgeschrittenen Stadium	Wachsende Patientengruppe	Möglicher Durchbruch bei der Behandlung

PharmaCyte Biotech, Inc. (PMCB) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete PharmaCyte Biotech Forschungs- und Entwicklungskosten in Höhe von 4,3 Millionen US-Dollar.

Ausgabenkategorie	Jährliche Kosten ($)
Zelltherapieforschung	2,100,000
Entwicklung der Behandlung von Bauchspeicheldrüsenkrebs	1,500,000
Verfeinerung der Technologieplattform	700,000

Investitionen in klinische Studien

Die Ausgaben für klinische Studien beliefen sich im Jahr 2023 auf insgesamt etwa 3,7 Millionen US-Dollar.

• Bauchspeicheldrüsenkrebs-Studie Phase I/II: 2.200.000 US-Dollar
• Kosten für die regulatorische Vorbereitung: 850.000 US-Dollar
• Patientenrekrutierung und -management: 650.000 US-Dollar

Aufrechterhaltung des geistigen Eigentums

Jährliche Kosten für geistiges Eigentum: 450.000 US-Dollar

IP-Kategorie	Jährliche Kosten ($)
Patentanmeldung und -pflege	250,000
Rechtsschutz	150,000
Internationaler Patentschutz	50,000

Personal- und wissenschaftliche Talentakquise

Gesamtpersonalaufwand für 2023: 5,2 Millionen US-Dollar

• Leitender wissenschaftlicher Mitarbeiter: 2.600.000 US-Dollar
• Forschungswissenschaftler: 1.800.000 US-Dollar
• Verwaltungspersonal: 800.000 US-Dollar

Einhaltung gesetzlicher Vorschriften und Genehmigungsprozesse

Kosten für die Einhaltung gesetzlicher Vorschriften: 1,1 Millionen US-Dollar

Compliance-Bereich	Jährliche Kosten ($)
Interaktion und Einreichungen mit der FDA	450,000
Regulatorische Dokumentation	350,000
Compliance-Beratung	300,000

PharmaCyte Biotech, Inc. (PMCB) – Geschäftsmodell: Einnahmequellen

Mögliche zukünftige Lizenzvereinbarungen

Bis zum Jahr 2024 hat PharmaCyte Biotech keine konkreten Zahlen zu den Lizenzeinnahmen bekannt gegeben. Die potenzielle Lizenzierungsstrategie des Unternehmens konzentriert sich auf seine Technologieplattform Cell-in-a-Box®.

Forschungsstipendien und Finanzierung

Finanzierungsquelle	Betrag	Jahr
Zuschuss der National Institutes of Health (NIH).	$298,000	2023
Zuschuss für Small Business Innovation Research (SBIR).	$224,500	2022

Mögliche Kommerzialisierung therapeutischer Behandlungen

Der Hauptfokus von PharmaCyte liegt weiterhin auf der Entwicklung von Behandlungen für:

• Bauchspeicheldrüsenkrebs
• Diabetes
• Hirntumor

Monetarisierung von geistigem Eigentum

PharmaCyte hält 7 aktive Patentfamilien ab 2024, mit möglichen zukünftigen Monetarisierungsstrategien.

Strategische Partnerschaftskooperationen

Partner	Fokus auf Zusammenarbeit	Potenzieller Wert
Universität Wien	Bauchspeicheldrüsenkrebsforschung	450.000 US-Dollar Forschungsunterstützung
MD Anderson Krebszentrum	Zusammenarbeit bei klinischen Studien	375.000 US-Dollar Forschungsförderung

Die gesamten potenziellen Einnahmequellen für 2024 werden auf geschätzt $1,547,500.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Value Propositions

PharmaCyte Biotech, Inc.'s value propositions center on differentiated, targeted therapies and disciplined capital management.

Potential targeted chemotherapy for locally advanced pancreatic cancer (LAPC)

PharmaCyte Biotech, Inc. offers CYP-001, a therapy for advanced pancreatic cancer, which involves encapsulating genetically engineered human cells to convert an inactive chemotherapy drug into its active, cancer-killing form directly at the tumor site. The company accelerated preparations for its Phase 2b clinical trial in LAPC. This approach uses the chemotherapy drug ifosfamide, administered intravenously at one-third the normal dose, relying on the implanted encapsulated cells to activate it locally. Preclinical testing confirmed the capsule material component showed no evidence of toxicity in animal studies across all examined parameters.

Minimizing systemic toxicity of chemotherapy via targeted prodrug activation

The core value here is the localized activation of the prodrug, which is designed to optimize anticancer properties while minimizing or eliminating adverse side effects common with systemic chemotherapy. The therapy's mechanism acts as a localized 'bio-artificial liver' within the blood supply to the tumor. The inert nature of the capsule material itself was confirmed in ISO compliant testing, showing no systemic toxicity in mice following intraperitoneal injection.

Potential bio-artificial pancreas for Type 1 and Type 2 diabetes

PharmaCyte Biotech, Inc. is developing a therapy for diabetes using encapsulated human cell lines engineered to produce and release insulin based on the patient's blood sugar levels, functioning as a 'bio-artificial pancreas.' This addresses a significant market. The global Diabetes Care Devices market was estimated at $65.74 billion in 2025. Type 2 Diabetes accounted for 88.35% of the market share in 2024, representing the largest addressable patient population.

Here's a quick look at the market context for the diabetes segment:

Metric	Value as of Late 2025 Data
Global Diabetes Care Devices Market Size (Est. 2025)	$65.74 billion
Projected CAGR (2025-2030)	6.94%
Type 2 Diabetes Market Share (2024)	88.35%

Strategic investment returns to maximize shareholder value

PharmaCyte Biotech, Inc. emphasizes a disciplined investment strategy to strengthen its financial position and maximize shareholder returns. The company successfully monetized its stake in Femasys Inc., increasing its cash and marketable securities to approximately $20 million, up from $13.3 million as of July 31, 2025. Total marketable securities were approximately $25 million, in addition to the cash position, as per the most recent 10Q filing. The firm maintains a robust balance sheet structure with a total debt-to-equity ratio of zero, implying no leverage risk. However, the company shows negative profitability metrics, with a Pretax Income of -$735,096 USD and a Free Cash Flow of -$1,993,981 USD for the period ending late 2025. The Return on Assets was -3.94% and Return on Equity was -7.71%. As of December 4, 2025, the Market Cap stood at $8.9 million, reflecting a decrease of -29.35% over one year. The Price to Book ratio was 0.12, while the Quick Ratio was 12.7, indicating strong liquidity.

Key financial structure points as of July 31, 2025, include:

• Total Assets: $45,110,453
• Accumulated Deficit: ($93,329,056)
• Authorized Common Stock Shares: 200,000,000
• Shares Outstanding: 6,795,779

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Customer Relationships

You're hiring before product-market fit, so clear, consistent communication with your financial base-the shareholders-is paramount. PharmaCyte Biotech, Inc. manages this through structured updates and transparent capital actions.

High-touch communication with shareholders via strategic updates

PharmaCyte Biotech, Inc. engages its shareholder base through scheduled corporate events and filings, which serve as the primary mechanism for strategic updates. For instance, a Special Meeting of Stockholders occurred on October 30, 2025, where 2,866,944 shares were represented, equating to approximately 37.1% of the outstanding voting stock entitled to vote.

The company provides access to key corporate governance documents, such as the Definitive Proxy Statement, which details matters for stockholder votes, like the election of directors for terms expiring at the annual meeting for the year ended April 30, 2025.

• Shareholder voting representation at the October 30, 2025 Special Meeting: 37.1%.
• Shares represented at the October 30, 2025 Special Meeting: 2,866,944.
• Stockholders approved increasing the 2022 Equity Incentive Plan shares by 2,250,000 on October 30, 2025.

Regulatory relationship management with the U.S. FDA

The relationship management with the U.S. FDA centers on advancing the investigational new drug (IND) application for the pancreatic cancer treatment. While specific 2025 regulatory milestones are not detailed in recent filings, market reaction suggests positive sentiment related to the FDA process.

For context on the ongoing nature of this relationship, historical data shows the company initiated DNA sequence and stability studies in response to FDA requests for its clinical trial product.

• Stock price movement on December 04, 2025, was up 31.91% following reports of 'FDA approval excitement.'
• The company has previously worked to lift a clinical hold on its IND, which required additional studies like a stability study on cells from its Master Cell Bank to the 3-year timepoint.

Investor relations focused on capital deployment transparency

Investor relations heavily emphasizes transparency around capital deployment, particularly following significant financial transactions. The successful monetization of the Femasys Inc. stake is a key recent example of this strategy in action.

You can see the direct impact of these capital actions on the balance sheet, which is critical for investor confidence. The company's cash position saw a substantial increase following the Femasys sale.

Here's the quick math on the cash position change:

Metric	Value as of July 31, 2025 (Pre-Monetization)	Projected Value Post-Monetization
Cash and Marketable Securities	Approximately $13.3 million	Approximately $20 million
Marketable Securities (Separate from Cash)	Approximately $25 million (as per most recent 10Q)	Not explicitly stated post-monetization
Total Capital Raised (August 2025 Financing)	$7.0 million	N/A
Q/C Investment Closed	$3,000,000 (Closed September 4, 2025)	N/A

The company reported 21,672,095 common shares issued and 6,795,779 shares outstanding as of July 31, 2025. The stock recently traded at $0.65 per share, with approximately 6.8 million shares outstanding, and the price saw a 9.9% increase on December 05, 2025.

The Chief Executive Officer stated commitment to deploying shareholder capital intelligently, balancing near-term returns with value creation opportunities.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Channels

The channels PharmaCyte Biotech, Inc. (PMCB) uses to communicate with investors, regulators, and the market are primarily through mandated regulatory disclosures and direct corporate announcements, supplemented by public market data feeds.

SEC Filings (10-K, 10-Q, 8-K) for financial and strategic updates

PharmaCyte Biotech, Inc. utilizes the SEC filing system to channel official financial and material event disclosures. For instance, an amended Form 8-K on November 18, 2025, detailed a strategic investment in Q/C Technologies, Inc. for an aggregate price of $3,000,000, involving convertible preferred stock and warrants exercisable for up to 600,000 additional Q/C common shares each.

Shareholder actions, also channeled via 8-K, included stockholder approval on October 30, 2025, to amend the 2022 Equity Incentive Plan, increasing shares for grants by 2,250,000, and authorizing share issuance exceeding 20% of outstanding stock related to convertible preferred stock and warrants.

Key balance sheet figures are reported through these filings. As of April 30, 2025, PharmaCyte Biotech, Inc. reported approximately $15.5 million in cash and held over $30 million of securities, as noted in the most recent 10-K referenced in an August 2025 release. The company's latest reported net income for the last quarter was $\text{-}8.36 \text{ M USD}$.

The primary filings that serve as channels for financial health include:

• 10-K Filing: Year End Results for the period ending April 30, 2025.
• 10-Q Filing: Quarterly Results for Q3 2025, released January 31, 2025.
• 8-K Filing: Material Event reported on October 31, 2025.

Corporate Press Releases for clinical and investment news

Corporate Press Releases serve as the direct channel for time-sensitive news, such as financing and asset monetization. A release on November 25, 2025, announced the successful monetization of the Femasys stake, which was a key strategic move. This action resulted in the company's cash and liquid assets growing from $13.3M to a total of $20M.

Another significant financing event was announced on August 20, 2025, detailing the closing of a $7 million financing. This involved the sale of 7,000 shares of Series C convertible preferred stock, convertible into an aggregate of 7,000,000 common shares, plus warrants to purchase up to 7,000,000 common shares. The preferred stock accrues a 7.0% quarterly dividend payable in cash.

Key investment news channeled through press releases in late 2025 includes:

• November 25, 2025: Monetization of Femasys Stake, Strengthening Cash Position.
• September 2, 2025: Increase in Stake in TNF Pharmaceuticals.
• August 20, 2025: Closing of $7 Million Financing.

Nasdaq Stock Exchange for public trading and liquidity

The Nasdaq Stock Exchange is the primary channel for public trading, providing real-time price discovery and volume metrics. As of December 3, 2025, the closing price was $0.7846, reflecting a 5.02% increase on that day, with a trading volume of 669,051 shares. The company is listed on the NASDAQ-CM.

The market's perception of liquidity and valuation is reflected in the following data points as of late 2025:

Metric	Value	Date/Context
Market Capitalization	$8.22 M	Late 2025
Market Capitalization	$6.00 M	Late 2025
52 Week High	$1.90	Last 52 Weeks
52 Week Low	$0.63	Last 52 Weeks
All-Time Low Price	$0.6300 USD	Reached November 19, 2025
Trading Range	$0.61 (Low) to $1.20 (High)	November 25, 2025
Average Daily Volume	5.83 M	Average
Employees	2	As of December 5, 2025

The stock has shown recent price movement, falling $\text{-}9.81%$ compared to the previous week and $\text{-}24.38%$ over the last year. The company does not pay dividends.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Customer Segments

You're mapping out the core groups PharmaCyte Biotech, Inc. (PMCB) needs to serve to make its Cell-in-a-Box® technology a commercial success. This isn't just about the end-user patient; it's about the entire ecosystem that enables the therapy to reach them, starting with the capital that funds the journey.

Biotech Investors and Shareholders seeking capital appreciation

This segment is crucial right now as PharmaCyte Biotech, Inc. (PMCB) is pre-revenue, with reported revenue of $0 million for the fiscal year ended April 30, 2025. Their interest is tied directly to the company's financial health and future potential. As of the latest reports, the company recently closed a $7.0 million financing in August 2025. The market capitalization as of September 15, 2025, was $7M, with the stock trading at $1.03. Ownership structure shows that Institutional Ownership stands at 8.57%, while Insider Ownership is 10.64%. The share count provides context for potential dilution and per-share value; as of July 31, 2025, there were 21,672,095 shares issued, with approximately 6.8 million common shares outstanding as of August 20, 2025. The company reported a net loss of -$8.36M last economic quarter, though net income for the fiscal year ending April 30, 2025, was $30.66 million, largely due to investment gains.

Oncologists and Hepatologists treating LAPC (future)

These are the specialists who will prescribe and manage the CypCaps™ therapy for locally advanced, inoperable pancreatic cancer (LAPC). The target market size for this indication is defined by the incidence of pancreatic cancer. For 2025 in the U.S., an estimated 67,440 new cases are projected. PharmaCyte Biotech, Inc. (PMCB)'s therapy targets the localized stage, which accounted for 15% of cases diagnosed between 2015 and 2021. The sheer number of specialists required to treat this patient base is significant, though a specific count for Hepatologists is not available. We can look at the broader oncology workforce as a proxy for the treating specialists.

Specialist Group	Relevant Count/Statistic	Date/Period of Data	Source Context
Total Actively Practicing Oncologists (U.S.)	25,419	2025	Active practice in the United States
Oncologists Billing Medicare (U.S.)	14,547	2024	Reported number
Hematology/oncology Physicians Tracked	11,937	October 2025	Most common tracked specialty
Medical Oncology Physicians Tracked	4,778	October 2025	Tracked specialty
Projected U.S. Oncologist Shortage	2,250	By 2025	Earlier projection

Patients with locally advanced, inoperable pancreatic cancer (future)

This is the initial, high-unmet-need patient population for the CypCaps™ product candidate. The overall pancreatic cancer incidence in the U.S. for 2025 is estimated at 67,440 new cases. The five-year relative survival rate for localized disease is 43.6%, compared to 3.2% for distant metastatic disease. The company's technology involves implanting encapsulated cells near the tumor site to activate a chemotherapy drug like ifosfamide.

Patients with insulin-dependent Type 1 and Type 2 diabetes (future)

This represents a significant, long-term expansion market for PharmaCyte Biotech, Inc. (PMCB)'s platform technology. The market for diabetes treatments is substantial, with the global Type 2 Diabetes Market size valued at $40.09 billion in 2025, and the U.S. segment at $10.82 billion. For Type 1 Diabetes, the global market was estimated at $16.97 Bn in 2025. The patient base in North America alone is large, with over 29 million people affected by diabetes, projected to rise to 32 million by 2025. Globally, the total number of people living with diabetes was 588.71 million in 2024.

• Global Type 2 Diabetes Market Size (2025): $40.09 billion
• U.S. Type 2 Diabetes Market Size (2025): $10.82 billion
• Global Type 1 Diabetes Market Size (2025 Estimate): $16.97 Bn
• North America Diabetes Prevalence (2025 Projection): 32 million people
• Global Diabetes Prevalence (2024): 588.71 million people

The Diabetes Stem Cell Therapy Market itself was valued at $5.4 Bn in 2024.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Cost Structure

You're looking at the core outflows for PharmaCyte Biotech, Inc. as of late 2025. For a company in clinical development, the cost structure is almost entirely non-revenue generating, focused on compliance, science, and keeping the lights on. It's a lean operation, but the costs associated with regulatory hurdles are significant.

The most immediate, non-recurring cost pressure comes from resolving the FDA clinical hold on the Investigational New Drug Application for pancreatic cancer. PharmaCyte Biotech, Inc. has engaged in specific service agreements to address the FDA's requests. The estimated total cost for these efforts is $212,000, with a portion of that, $157,000, specifically related to services from SG Austria and its subsidiaries to generate the necessary data submissions. This is a direct, targeted cost to unlock future revenue potential.

Research and Development (R&D) expenses, along with General and Administrative (G&A) expenses, form the bulk of the recurring operational spend. Looking at the quarter ended January 31, 2025, the total operating expenses were $960,252. For the nine-month period ending January 31, 2025, these operating expenses totaled $3,335,998. To be fair, these figures reflect a conscious reduction in costs from the prior year, specifically citing decreases in R&D costs, director fees, and general administrative costs.

Here's a quick look at the scale of those operating costs relative to the top-line result for that nine-month period:

Cost Category	Amount (Nine Months Ended Jan 31, 2025)
Total Operating Expenses	$3,335,998
Estimated FDA Hold Related Costs (Partial)	$212,000
Net Loss (Recent Quarter)	Approximately -$8.36 million

Personnel costs are kept to an absolute minimum, which is a key factor in managing the burn rate. As of April 30, 2025, PharmaCyte Biotech, Inc. maintained a very small core team, reporting only 2 employees. This minimal headcount directly contributes to lower compensation expenses, though compensation was still a line item that saw reductions in the nine months ended January 31, 2025.

The ultimate measure of the cost structure's impact on the bottom line is the net loss. For a recent economic quarter, the company reported a significant net loss of approximately -$8.36 million. This loss figure, while substantial, is viewed against a backdrop of strong liquidity following strategic asset monetization, suggesting management is funding the current cost base from reserves rather than immediate operations.

The cost structure is characterized by:

• Regulatory compliance spending directly tied to FDA resolution.
• Curtailment of R&D spending to conserve capital.
• Minimal G&A overhead due to a lean structure.
• Personnel costs anchored by a team of 2 employees.

Finance: draft 13-week cash view by Friday.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of PharmaCyte Biotech, Inc.'s business model as of late 2025. For a company focused on clinical development, the revenue streams are currently dominated by non-operational activities, namely strategic capital deployment and financing events, rather than product sales.

Investment Gains from Strategic Capital Deployment

PharmaCyte Biotech, Inc. executed a significant move in late 2025 by successfully monetizing its stake in Femasys Inc. (NASDAQ: FEMY). This action validated the Company's strategic approach to capital allocation. Following this monetization, PharmaCyte's cash and marketable securities are expected to increase to approximately $20 million, which is up from $13.3 million as of July 31, 2025. This transaction is part of a broader strategy to strengthen the balance sheet.

To give you the full picture of the liquidity position around this event, here's a look at the key figures:

Metric	Date/Period End	Amount	Context
Cash and Securities	April 30, 2025	Approximately $15.5 million in cash and over $30 million in securities
Cash and Securities	July 31, 2025	$13.3 million
Capital Raise Proceeds	August 2025	$7 million
Cash and Securities (Expected Post-Monetization)	November 2025	Approximately $20 million
Total Cash and Marketable Securities (Post-Monetization)	November 2025	Roughly $20 million in cash plus approximately $25 million in marketable securities

The company is committed to deploying shareholder capital intelligently, balancing near-term returns with sustained value creation opportunities.

Recent Capital Raise

PharmaCyte Biotech, Inc. closed a financing round in August 2025, securing $7 million. This was achieved through a private placement involving the sale of Series C convertible preferred stock. The successful completion of this financing strengthened the balance sheet, providing financial flexibility to support ongoing business initiatives.

Key details of the August 2025 raise include:

• The financing involved the sale of 7,000 shares of Series C preferred stock.
• Each preferred share had a stated value of $1,000.
• The preferred stock is convertible into an aggregate of 7,000,000 shares of common stock.
• The conversion price is $1.00 per share of common stock.
• Unregistered common stock purchase warrants were issued to purchase up to 7,000,000 shares of common stock.
• Warrants are exercisable immediately at an exercise price of $1.00 per share for a term of five years.
• As of the release date, PharmaCyte had approximately 6.8 million shares of common stock outstanding.

Future Potential Licensing or Collaboration Revenue

As of late 2025, PharmaCyte Biotech, Inc. reports its future potential licensing or collaboration revenue as $0.

Future Potential Product Sales of CypCaps™

The Company's lead product candidate, CypCaps™, which uses the Cell-in-a-Box® technology for cellular therapies, currently generates no direct product sales revenue. As of late 2025, future potential product sales of CypCaps™ are reported as $0.

It's important to note that PharmaCyte Biotech's total operating revenue for the fiscal year 2025 ending April 30, 2025, was reported as $0.0. For the three months ended January 31, 2025, the total operating revenue was reported as -960,252 yuan, which was an improvement from the prior year's equivalent loss.